Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login


Inflammatory bowel disease

Type 2 diabetes drug may be associated with inflammatory bowel disease

Early results from a trial investigating the link between antidiabetic drugs and autoimmune diseases may have found an association, researchers have revealed

Crohn's disease, endoscope view

Source: Gastrolab / Science Photo Library

Researchers found that use of dipeptidyl peptidase-4 inhibitors was associated with a 75% increased risk of inflammatory bowel disease 

The use of dipeptidyl peptidase-4 (DPP-4) inhibitors in type 2 diabetes has increased in the past decade. However, the effect of the DPP-4 enzyme in autoimmune diseases, such as inflammatory bowel disease (IBD), is not well understood.

Researchers carried out a population-based cohort study looking at 141,170 adults who started antidiabetic drugs between 1 January 2007 and 31 December 2016, with follow-up until 30 June 2017[1].

During follow-up, 208 incident IBD events occurred. The researchers found that, compared with use of other antidiabetic drugs, use of DPP-4 inhibitors was associated with a 75% increased risk of IBD (53.4 vs 34.5 per 100,000 person years; hazard ratio 1.75; 95% confidence interval: 1.22–2.49). The risk was found to increase with duration of use (up to three to four years) and decrease after four years.

Although these findings need to be replicated, doctors should be aware of this possible association and perhaps refrain from prescribing DPP-4 inhibitors for people at high risk, the researchers concluded in the British Medical Journal (21 March 2018).

Citation: Clinical Pharmacist DOI: 10.1211/CP.2018.20204651

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • BNF and British National Formulary for Children

    BNF and British National Formulary for Children

    Now available as a 2 year print subscription to both the BNF and British National Formulary for Children, ensuring you have the latest medicines information as it publishes and at a greatly reduced price.

    £262.50Buy now
  • Drugs of Abuse

    Drugs of Abuse

    A concise, easy-to-read guide for healthcare professionals who encounter drug abuse.

    £38.00Buy now
  • Pharmaceutical Toxicology

    Pharmaceutical Toxicology

    Explains the methodology and requirements of pre-clinical safety assessments of new medicines. Includes registration requirements and pharmacovigilance.

    £40.00Buy now
  • Adverse Drug Reactions

    Adverse Drug Reactions

    A practical guide to the drug reactions that affect particular organ systems, and the management of these reactions.

    £38.00Buy now
  • English Delftware Drug Jars

    English Delftware Drug Jars

    This beautiful book illustrates the art and history of the collection of English delftware drug jars in the Museum of the Royal Pharmaceutical Society of Great Britain.

    £54.00Buy now
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Crohn's disease, endoscope view

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.